NCT02732171

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse. Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Patients who harbor DTCs will be offered the opportunity for enrollment into a clinical trial of therapy targeting DTCs to prevent recurrence (separate protocols).

Conditions

• Breast Cancer

Interventions

Type	Name	Description
OTHER	Research Blood Collection	Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)

Timeline

• Start date: 2016-04-01
• Primary completion: 2028-04-01
• Completion: 2030-04-01
• First posted: 2016-04-08
• Last updated: 2025-08-01

Locations

1 site across 1 country: United States